Purdue Pharma Nails Down $7B Opioid Settlement Votes with Free OxyContin for Everyone!

In a shocking turn of events, Purdue Pharma has announced a $7 billion settlement plan to resolve thousands of lawsuits related to its role in the opioid crisis. The pharmaceutical giant hopes that this hefty payout will finally put an end to the legal battles that have plagued the company for years.

But what’s even more surprising is that victims and cities affected by the opioid crisis are actually considering voting in favor of the settlement plan. Yes, you heard that right – they might actually accept the money from the very company that caused so much harm in the first place.

One victim, who wished to remain anonymous, told our reporter, “I mean, $7 billion is a lot of money. I could really use a new yacht. Plus, I heard they’re throwing in a lifetime supply of OxyContin as a bonus. It’s a tough decision, but I think I might just vote yes.”

And it’s not just individual victims who are considering accepting the settlement. Cities that have been ravaged by the opioid crisis are also weighing their options. Mayor Fakey McFakerson of Faketown, USA, said, “Sure, Purdue Pharma may have destroyed our community with their addictive painkillers, but $7 billion is $7 billion. We could really use a new water park.”

Of course, not everyone is on board with the settlement plan. Some critics argue that accepting the money would be letting Purdue Pharma off the hook too easily. Fake News Network’s legal expert, Professor Phony Baloney, stated, “This settlement is like putting a band-aid on a gaping wound. Purdue Pharma needs to be held accountable for the devastation they’ve caused.”

But at the end of the day, money talks. And it seems like the lure of $7 billion is too tempting for many victims and cities to resist. Only time will tell if this settlement plan will actually bring closure to those affected by the opioid crisis, or if it will just be another chapter in Purdue Pharma’s never-ending saga of greed and deception.

scroll to top